---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-100668"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:22:31.714536+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics appoints Blai Coll as CMO, Ashley Hall as CDO; Mark Bach departs in planned succession

## Summary
- Mark Bach to depart as CMO effective Sept 18; will serve as advisor through Dec 31.
- Blai Coll, previously VP of Clinical Development, promoted to CMO effective Sept 18.
- Ashley Hall appointed as newly created Chief Development Officer role.
- GSBR-1290 Phase 2b for obesity planned for Q4 2024.
- Dr. Coll led GSBR-1290 program; Ms. Hall brings regulatory experience from Repatha.

## SEC filing metadata
- accession: 0001104659-24-100668
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465924100668/0001104659-24-100668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465924100668/tm2424160d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-100668
- JSON: https://secwatch.observer/filing/0001104659-24-100668.json
- Plain text: https://secwatch.observer/filing/0001104659-24-100668.txt

## Key facts
- Executive change
  Mark Bach departed as Chief Medical Officer at Structure Therapeutics Inc..
  - Action: departed
  - Role: Chief Medical Officer
  source text: On September 12, 2024, Mark Bach, M.D., Ph.D. entered into a separation and consulting agreement (the “Bach Separation and Consulting Agreement”) with Structure Therapeutics Inc. (the “Company”) in connection with his departure as Chief Medical Officer (“CMO”) as part of a planned succession, effective as of September 18, 2024 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465924100668/0001104659-24-100668-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.